About Perforin-1
Perforin-1 (PRF1) is a protein
from Homo sapiens identified by UniProt accession
P14222, 555 residues long.
MolForge cross-references it against 0 known binders and
939 disease associations.
Target properties
| Protein name | Perforin-1 |
| UniProt accession | P14222 |
| Gene | PRF1 |
| Organism | Homo sapiens |
| Length | 555 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (939)
Diseases linked to this target (Open Targets).
- Familial hemophagocytic lymphohistiocytosis · score 0.83
- Aplastic anemia · score 0.65
- lymphoma · score 0.63
- autoinflammatory syndrome · score 0.52
- genetic disorder · score 0.52
- lymphocyte count · score 0.47
- lymphocyte percentage of leukocytes · score 0.42
- type 1 diabetes mellitus · score 0.40
- neutrophil percentage of leukocytes · score 0.39
- aplastic anemia · score 0.37
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-P14222-F1 | alphafold | PREDICTED | 90.71 | — |
Amino-acid sequence (555 residues)
MAARLLLLGI LLLLLPLPVP APCHTAARSE CKRSHKFVPG AWLAGEGVDV TSLRRSGSFP VDTQRFLRPD GTCTLCENAL QEGTLQRLPL ALTNWRAQGS GCQRHVTRAK VSSTEAVARD AARSIRNDWK VGLDVTPKPT SNVHVSVAGS HSQAANFAAQ KTHQDQYSFS TDTVECRFYS FHVVHTPPLH PDFKRALGDL PHHFNASTQP AYLRLISNYG THFIRAVELG GRISALTALR TCELALEGLT DNEVEDCLTV EAQVNIGIHG SISAEAKACE EKKKKHKMTA SFHQTYRERH SEVVGGHHTS INDLLFGIQA GPEQYSAWVN SLPGSPGLVD YTLEPLHVLL DSQDPRREAL RRALSQYLTD RARWRDCSRP CPPGRQKSPR DPCQCVCHGS AVTTQDCCPR QRGLAQLEVT FIQAWGLWGD WFTATDAYVK LFFGGQELRT STVWDNNNPI WSVRLDFGDV LLATGGPLRL QVWDQDSGRD DDLLGTCDQA PKSGSHEVRC NLNHGHLKFR YHARCLPHLG GGTCLDYVPQ MLLGEPPGNR SGAVW
Explore Perforin-1 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets